tachycardia
TACHYCARDIA

Tachycardia or tachyarrhythmia is used to describe the presence of cardiac rhythm abnormality in states when cardiac rate is increased to >100 bpm.

Divided into supraventricular and ventricular tachycardia.

Signs and symptoms related to rapid heart rate are altered sensorium, angina, shortness of breath, myocardial infarction, hypotension and other signs of shock (eg cold clammy skin, low urine output), heart failure or pulmonary congestion.

Control Strategy for Atrial Fibrillation

  • Lenient heart rate (HR) control, compared to strict HR control, may be beneficial in patients with persistent atrial fibrillation who have stable ventricular function (left ventricular [LV] ejection fraction >0.40) and/or no symptoms related to atrial fibrillation
    • LV function should be monitored in these patients
    • Lenient HR control is defined as achieving resting HR <110 beats per minute (bpm); strict HR control is <80 bpm at rest and HR <110 bpm during a 6-minute walk
  • One trial revealed that in patients with atrial fibrillation and systolic heart failure, routine strategy of rhythm control is not beneficial compared to rate control strategy
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 6 days ago
Use of aspirin in the primary prevention of cardiovascular disease (CVD) in patients with no prior CVD history yields protection against the risks of acute myocardial infarction (AMI) and ischaemic stroke, but at the expense of an increase of similar magnitude in the incidence of major bleeding, according to the results of a recent meta-analysis presented at the European Society of Cardiology (ESC) Congress 2019 in Paris, France.
Dr Margaret Shi, 5 days ago

A comprehensive model of care delivered by nonphysician health workers (NPHWs), involving primary care physicians and families that was informed by local context, substantially improved blood pressure (BP) control and cardiovascular disease (CVD) risk, according to results of the HOPE 4 trial reported at the European Society of Cardiology (ESC) Congress 2019 and World Congress of Cardiology (WCC) 2019.